High-throughput viability assays are a cornerstone of screening cascades to guide SAR in oncology drug development. In the early stages of drug discovery, cell-based assays are indispensable for understanding the functional effects of new therapeutic agents. Our portfolio encompasses high-throughput assays to assess fundamental cell health indicators such as proliferation, viability and cytotoxicity, as well as more complex assays to quantify cell cycle alterations, senescence, apoptosis and more.
DNA damage is one of the most ubiquitous mechanisms of action exploited in cancer therapy. Rapid proliferation rates and the presence of damaging mutations in DNA repair pathway genes make cancer cells highly susceptible to insult to their genomic material, and classic radiation and chemotherapy treatments exploit this weakness. More targeted approaches to induce damage or prevent repair seek to overcome resistance by exploiting new targets. Conversely, DNA damage quantification is crucial to determine potential genotoxicity of new compounds, which is a key concern in assessing their safety profile.